Botanical species · safety record

Chromolaena odorata

The EFSA Compendium of Botanicals holds 8 constituent measurements and 3 adverse-effect records for Chromolaena odorata. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Chromolaena odorata (L.) R.M.King & H.Rob.

8Constituent measurements

3Safety records

5Cited sources

0Licensed products (Canada)

Also recorded as

Eupatorium odoratum L.

Synonyms are carried from the source compendium. A species may be traded and studied under more than one name, which is exactly how a safety record gets lost.

Regulatory presence

No Health Canada licensed natural health product in the snapshot names this species as a medicinal ingredient under this exact binomial. Absence here means absence from this one register under this one name, not absence from trade, and not a safety verdict.

What the records describe

Constituents measured

Plant parts

Preparations

Effect types

Target tissues

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
Unsaturated pyrrolizidine alkaloids	Unspecified	—	—	Unspecified	Resolve DOI
Alkaloids	Live plants	—	—	Phytochemical screening	No resolvable identifier
Chrysophanol	Roots and other underground parts	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	No resolvable identifier
Cyanogenic glycosides	Live plants	—	0.13 Percent	Phytochemical screening	No resolvable identifier
Physcion	Roots and other underground parts	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	No resolvable identifier
Phytic acid	Live plants	—	0.54 Percent	Phytochemical screening	No resolvable identifier
Saponins	Live plants	—	1.98 Percent	Phytochemical screening	No resolvable identifier
Tannins	Live plants	—	0.37 Percent	Phytochemical screening	No resolvable identifier

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

Effect	Target tissue	Plant part	Preparation	Test organism	Test type	Source
Endocrine	Testes	Leaves	Solvent extraction	Rat (as animal)	Reproduction toxicity	Resolve DOI
Hepatotoxicity	Liver	Leaves	Solvent extraction	Rat (as animal)	Short-term toxicity	No resolvable identifier
Nephrotoxicity	Urogenital: kidneys	Leaves	Solvent extraction	Rat (as animal)	Short-term toxicity	No resolvable identifier

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

Igboh, M.N., Ikewuchi, J.C., Ikewuchi, C.C. Chemical profile of Chromolaena odorata L. (King and Robinson) leaves. Pakistan Journal of Nutrition, 2009, vol. 8, no. 5, p. 521-524.
Roeder, E., Wiedenfeld, H. Plants containing pyrrolizidine alkaloids used in the Traditional Indian Medicine - including Ayurveda. PHARMAZIE, 2013, vol. 68, no. 2, p. 83-92. DOI
Clement, Taziebou Lienou., Judith, Shang Dzelambon., Anatole, Pieme Constant., Justin, Essia Ngang Jean., Fracois-xavier, Etoa., Blaise, Nkegoum. Toxicological investigation of aqueous extracts of Chromolaena odorata leaves on rats and mice . Research journal of biotechnology, 2008, vol. 3, no. 3, p. 46-51.
Yakubu, Musa T. Effect of a 60-Day Oral Gavage of a Crude Alkaloid Extract From Chromolaena odorata Leaves on Hormonal and Spermatogenic Indices of Male Rats. JOURNAL OF ANDROLOGY, 2012, vol. 33, no. 6, p. 1199-1207. DOI
Amatya, S., Tuladhar, SM. Eupatoric acid: A novel triterpene from Eupatorium odoratum L. (Asteraceae) . Zeitschrift fur naturforschung section b-a journal of chemical sciences, 2005, vol. 60, no. 9, p. 1006-1011.

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature